Publications

  1. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol. 2017 Nov; 72 (5):660-664 Epub 2017 May 22
    View PubMed
  2. Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017 Aug 15; 23 (16):4704-4715 Epub 2017 May 04
    View PubMed
  3. Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. Eur Urol. 2017 Aug; 72: (2)300-306.
    View PubMed
  4. Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L. Low hypoxia inducible factor-1alpha (HIF-1alpha) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017 Aug; 29 (4):374-378
    View PubMed
  5. Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, Costello BA, Leibovich BC, Thompson RH, Cheville JC, Sukov WR. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017 Jul; 30: (7)998-1012.
    View PubMed
  6. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun; 15: (6)804-834.
    View PubMed
  7. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Tollefson MK, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol. 2017 Apr; 71: (4)560-567.
    View PubMed
  8. Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int. 2017 Mar; 119: (3)489-495.
    View PubMed
  9. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. J Urol. 2017 Mar; 197: (3 Pt 1)574-579.
    View PubMed
  10. Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, Boorjian SA, Costello BA, Thompson RH, Leibovich BC. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2017 Jan; 197: (1)44-49.
    View PubMed
  11. Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB, Lohse CM, Atwell TD, Costello BA, Leibovich BC, Thompson RH. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU Int. 2017 Jan; 119: (1)116-127.
    View PubMed
  12. Joyce DD, Psutka SP, Groeschl RT, Thompson RH, Boorjian SA, Cheville JC, Stewart-Merrill SB, Lohse CM, Costello BA, Que FG, Leibovich BC. Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology. 2017 Jan; 99:155-161.
    View PubMed
  13. Gershman B, Takahashi N, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU Int. 2016 Nov; 118: (5)742-749.
    View PubMed
  14. Psutka SP, Cheville JC, Costello BA, Stewart-Merrill SB, Lohse CM, Leibovich BC, Boorjian SA, Thompson RH. Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. Urology. 2016 Oct; 96:106-113 Epub 2016 July 21
    View PubMed
  15. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, Stewart-Merrill SB, Lohse CM, Cheville JC, Leibovich BC, Tollefson MK. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. J Urol. 2016 Feb; 195: (2)270-6.
    View PubMed
  16. Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC, Thompson RH. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol. 2016 Jan; 69: (1)84-91.
    View PubMed
  17. Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP, Jimenez RE, Costello BA, Frank I, Cheville JC. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology. 2015 Oct; 47: (6)533-42.
    View PubMed
  18. Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. A Phase III Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Aug 01; 21: (15)3420-7.
    View PubMed
  19. Zhang BY, Cheville JC, Thompson RH, Lohse CM, Boorjian SA, Leibovich BC, Costello BA. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. Eur Urol. 2015 Jul; 68: (1)5-7.
    View PubMed
  20. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular cancer, version 2.2015. J. Natl. Compr. Cancer Netw. 2015 Jun; 13(6):772-98.
  21. Smaldone MC, Handorf E, Kim SP, Thompson RH, Costello BA, Corcoran AT, Wong YN, Uzzo RG, Leibovich BC, Kutikov A, Boorjian SA. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. J Urol. 2015 Apr; 193(4):1108-13. Epub 2014 Oct 23.
    View PubMed
  22. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA. A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2015 Mar; 115(3):405-11. Epub 2014 Oct 19.
    View PubMed
  23. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13: (2)151-9.
    View PubMed
  24. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67: (1)33-41.
    View PubMed
  25. Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopolous J, Kanesvaran R, Lauer R, Sweeney C, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Doolin E, Bibby D, Simpson J, Iglesias J, Hutson T. 815PDA PHASE I/II TRIAL OF BNC105P WITH EVEROLIMUS IN METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF THE RANDOMIZED PHASE II DISRUPTOR-1 TRIAL. Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv283.
    View PubMed
  26. Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014 Aug; 192: (2)357-63.
    View PubMed
  27. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014 Aug; 32(4):710-6. Epub 2014 Apr 18.
    View PubMed
  28. Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014 May; 113(5b):E17-21. Epub 2013 Sep 05.
    View PubMed
  29. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014 May; 27(5):758-64. Epub 2013 Nov 1
    View PubMed
  30. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32(1):24.e1-6. Epub 2013 Mar 11
    View PubMed
  31. Patel K, Foster NR, Farrell A, Le-Lindqwister NA, Mathew J, Costello B, Reynolds J, Meyers JP, Jatoi A. Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ. 2013 Dec; 28: (4)770-6.
    View PubMed
  32. Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol. 2013 Oct; 64(4):600-6. Epub 2012 Dec 25.
    View PubMed
  33. Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR. NUT midline carcinoma: an aggressive intrathoracic neoplasm. J Thorac Oncol. 2013 Oct; 8(10):1335-8.
    View PubMed
  34. Eisenberg MS, Cheville JC, Thompson RH, Kaushik D, Lohse CM, Boorjian SA, Costello BA, Leibovich BC. Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. J Urol. 2013 Jul; 190: (1)37-43.
    View PubMed
  35. McDonnell S, Bevan G, Riska SM, Costello BA, Longenbach S, Dronca RS, Moynihan TJ, Pitot HC, Quevedo F, Cerhan JR. Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2013 Feb 20; 31: (6_suppl)75.
    View PubMed
  36. Marcelin JR, Jones JM, Costello BA. 41-year-old woman with fever, neutropenia, and elevated transaminase levels. Mayo Clin Proc. 2013 Jan; 88(1):113-6.
    View PubMed
  37. Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, Lohse CM, Leibovich BC. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancer. 2012 Sep 15; 118(18):4412-20. Epub 2012 Jan 03.
    View PubMed
  38. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, Shippee ND, Erwin PJ, Costello BA, Chow GK, Leibovich BC. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012 Jul; 188(1):51-7. Epub 2012 May 14.
    View PubMed
  39. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87: (3)240-6.
    View PubMed
  40. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011 Nov; 78(5):1101-6. Epub 2011 Sep 08.
    View PubMed
  41. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol. 2011 Nov; 186(5):1779-85. Epub 2011 Sep 25.
    View PubMed
  42. Boorjian SA, Tollefson MK, Cheville JC, Costello BA, Thapa P, Frank I. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol. 2011 Nov; 186(5):1796-802. Epub 2011 Sep 25.
    View PubMed
  43. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011 Jul 1; 117(13):2873-82. Epub 2011 Jan 10.
    View PubMed
  44. Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C, Allmer C, Leibovich BC. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol. 2011 Jun; 185(6):2035-9. Epub 2011 Apr 15.
    View PubMed
  45. Kohli M, Mahoney DW, Chai HS, Hillman DW, Rider DR, Costello BA, Cerhan JR. Variation in sex steroid methyl transferases associated with androgen deprivation therapy (ADT) efficacy in advanced prostate cancer. J Clin Oncol. 2011 May 20; 29: (15_suppl)4647.
    View PubMed
  46. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, Lane MA, Ehlers SL, Erwin PJ, Nowakowski KE, Murad MH. Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011 May 19; 9:2.
    View PubMed
  47. Kohli M, Mahoney DW, Chai HS, Hillman DW, Rider DR, Costello BA, Cerhan JR. Use of variation in sex steroid methyl transferases to predict efficacy of androgen-deprivation therapy (ADT) in advanced prostate cancer. J Clin Oncol. 2011 Mar; 29: (7_suppl)14.
    View PubMed
  48. Kohli M, Mahoney DW, Chai HS, Hillman DW, Rider DR, Costello BA, Cerhan JR. Variation in UDP glucouronyltransferase (UGT) genes associated with prostate cancer mortality. J Clin Oncol. 2011 Mar; 29: (7_suppl)44.
    View PubMed
  49. Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: Results from a population based cohort. International Braz J Urol. 2011; 37(5):663.
  50. Costello BA, Hecht JR, Grothey A. Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. J Clin Oncol. 2009 May 20; 27: (15_suppl)4054.
    View PubMed
  51. McLeod TG, Costello BA, Colligan RC, Dierkhising RA, Beebe TJ, Offord KP, Locke GR 3rd. Personality characteristics of health care satisfaction survey non-respondents. Int J Health Care Qual Assur. 2009; 22(2):145-56.
    View PubMed
  52. Costello BA, McLeod TG, Locke GR 3rd, Dierkhising RA, Offord KP, Colligan RC. Pessimism and hostility scores as predictors of patient satisfaction ratings by medical out-patients. Int J Health Care Qual Assur. 2008; 21(1):39-49.
    View PubMed
  53. Sharma S, Tleyjeh IM, Espinosa RE, Costello BA, Baddour LM. Pacemaker infection due to Mycobacterium fortuitum. Scand J Infect Dis. 2005; 37(1):66-7.
    View PubMed
  54. Sood V, Costello BA, Burge MR. How low can you go? Chronic hypoglycemia versus normal glucose homeostasis. J Investig Med. 2001 Mar; 49(2):205-9.
    View PubMed
  55. Costello BA, Roberts F. Medical recommendations as joint social practice. Health Commun. 2001; 13(3):241-60.
    View PubMed